Neurogene (NGNE) Long-Term Debt Issuances (2014)

Neurogene (NGNE) posted Long-Term Debt Issuances of -$5.2 million for Q4 2014, down 300.0% on a QoQ basis from $2.6 million in Q1 2014.

Neurogene (NGNE) Long-Term Debt Issuances (2014) Analysis & Trends

Neurogene's Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at -$5.2 million for Q4 2014.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$5.2 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was -$2.6 million (changed N/A YoY) and the FY2014 annual result came in at -$2.6 million, down 208.7% from the prior year.
Long-Term Debt Issuances was -$5.2 million for Q4 2014 at Neurogene, down from $2.6 million in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $2.6 million in Q1 2014 and bottomed at -$5.2 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Neurogene	776.69 Mn	776.69 Mn	-	-

Download Data